Latest Exelixis Inc (EXEL) Headlines
Exelixis Earnings Hindsight: Down 5.2% in Last 18 Days (EXEL)
Comtex SmarTrend(R) - Mon Mar 10, 7:41AM CDT
Two weeks ago on February 20th, 2014 Exelixis (NASDAQ:EXEL) reported earnings and analysts, on average, expected a loss of $0.38 on sales of $5.7 million. The company actually reported a loss of $0.38 per share on sales of $4.3 million, missing EPS estimates by $0.01 and missing revenue estimates by $1.4 million. Shares of Exelixis have slipped from $7.16 to $6.79, representing a loss of 5.2%, since the company reported earnings 18 days ago.
3 Stocks Under $10 to Trade for Breakouts
at The Street - Wed Mar 05, 5:00AM CST
These under-$10 stocks are within range of triggering breakout trades.
Exelixis Announces Webcast of March 4 Presentation at the 34th Annual Cowen and Company Health Care Conference
Business Wire - Wed Feb 26, 6:56PM CST
Exelixis, Inc. (NASDAQ:EXEL) today announced that Michael M. Morrissey, Ph.D., the company's president and chief executive officer, will present at the 34th Annual Cowen and Company Health Care Conference at 10:00 a.m. EST/7:00 a.m. PST on Tuesday, March 4, 2014 in Boston.
Exelixis Q4 Loss In Line with Expectations - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 21, 11:04AM CST
Exelixis reported fourth quarter 2013 net loss per share of 38 cents, in line with the Zacks Consensus Estimate.
Exelixis' Q4 Loss Widens as Investors Await Key Trial Data
Sean Williams, The Motley Fool - Motley Fool - Thu Feb 20, 4:28PM CST
Cancer-focused biopharmaceutical company Exelixis reported its fourth-quarter earnings results after the bell tonight, delivering lower revenue and a wider loss than in the year-ago period. For the quarter, Exelixis reported net product...
Exelixis Announces Fourth Quarter and Full Year 2013 Financial Results
Business Wire - Thu Feb 20, 3:15PM CST
Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the fourth quarter and year ended December 31, 2013.
Exelixis Inc elects Jeffrey J Hessekiel as EVP & general counsel
M2 - Thu Feb 13, 3:11AM CST
Biotechnology company Exelixis Inc (NasdaqGS:EXEL) revealed on Wednesday the addition of Jeffrey J Hessekiel, JD, as its executive vice president and general counsel.
Exelixis Appoints Executive Vice President and General Counsel
Business Wire - Wed Feb 12, 4:26PM CST
Exelixis, Inc. (NASDAQ: EXEL) today announced the appointment of Jeffrey J. Hessekiel, J.D., as executive vice president and general counsel. Mr. Hessekiel is a veteran legal professional with more than a decade of experience in the biopharmaceutical industry, as well as six years spent in general corporate and litigation practice in Silicon Valley. His legal expertise in pharmaceutical commercialization, compliance, and risk management will benefit Exelixis following its first product launch and in anticipation of top-line data from as many as four phase 3 pivotal trials later this year.
Exelixis Announces February 20th Webcast of Fourth Quarter and Full Year 2013 Financial Results Conference Call
Business Wire - Mon Feb 10, 3:35PM CST
Exelixis, Inc. (NASDAQ: EXEL) will release its fourth quarter and full year 2013 financial results on Thursday, February 20, 2014 after the markets close. The announcement will be followed by a live webcast at 5:00 p.m. EST/ 2:00 p.m. PST. During the webcast, Exelixis management will discuss the Company's financial results, financial outlook and development program and plans for cabozantinib, and also provide a general business update. The webcast may be accessed in the Event Calendar page under Investors & Media at www.exelixis.com.
J. J. Keller and Verizon Join Forces for an All-Inclusive E-Log Solution
Business Wire - Fri Feb 07, 8:48AM CST
Fleets now have an easier way to transition to E-Logs as J. J. Keller & Associates, Inc.(R) introduces the J. J. Keller Compliance Tablet(TM) powered by Verizon.
Western Asset Inflation Management Fund Inc. Portfolio Composition as of December 31, 2013
Business Wire - Thu Feb 06, 7:00AM CST
Western Asset Inflation Management Fund Inc. (NYSE: IMF) announces its portfolio composition as of December 31, 2013.
3 Stocks to Get on Your Watchlist
Sean Williams, The Motley Fool - Motley Fool - Wed Feb 05, 4:11PM CST
I follow quite a lot of companies, so the usefulness of a watchlist to me cannot be overstated. Without my watchlist, I'd be unable to keep up with my favorite sectors and see what's really moving the market. Even worse, I'd be lost when the time...
Exelixis Announces Webcasts of Investor Conference Presentations in February
Business Wire - Fri Jan 31, 4:48PM CST
Exelixis, Inc. (NASDAQ:EXEL) today announced that Michael M. Morrissey, Ph.D., the company's president and chief executive officer, will present at the following two investor conferences in February:
Exelixis Set to Possibly Rebound After Yesterday's Selloff of 1.97%
Comtex SmarTrend(R) - Tue Jan 28, 5:40PM CST
Exelixis (NASDAQ:EXEL) traded in a range yesterday that spanned from a low of $6.81 to a high of $7.22. Yesterday, the shares fell 2.0%, which took the trading range below the 3-day low of $6.85 on volume of 7.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Exelixis Announces Pricing of Overnight Offering of 10,000,000 Shares of Common Stock
Business Wire - Thu Jan 23, 7:33AM CST
Exelixis, Inc. (Nasdaq: EXEL) today announced the pricing of its overnight underwritten public offering of 10,000,000 shares of newly issued common stock at a price to the public of $8.00 per share. Exelixis also granted the underwriter a 30-day option to purchase up to an additional 1,500,000 shares of common stock in connection with the offering. All of the shares of common stock in the offering are being sold by Exelixis. Exelixis anticipates that its aggregate net proceeds from the offering will be $75.6 million after deducting the underwriting discount and estimated offering expenses payable by Exelixis (assuming no exercise of the underwriter's option to purchase additional shares).
Exelixis plans overnight public offering of 10m common shares
M2 - Thu Jan 23, 5:25AM CST
US-based biotechnology company Exelixis Inc (NasdaqGS:EXEL) said on Wednesday that it intends to offer 10m shares of its common stock in an overnight underwritten public offering.
Exelixis Launches Proposed Overnight Public Offering of Common Stock
Business Wire - Wed Jan 22, 3:00PM CST
Exelixis, Inc. (Nasdaq: EXEL) today announced that it plans to offer, subject to market and other conditions, 10,000,000 shares of its common stock in an overnight underwritten public offering. The company expects to grant the underwriter a 30-day option to purchase up to an additional 1,500,000 shares of common stock in connection with the offering. All of the shares of common stock in the offering will be sold by Exelixis. Subject to market and other conditions, the offering is expected to price before 9:30 a.m., EST, on January 23, 2014.
Uptrend Call Working As Exelixis Stock Rises 51.7% (EXEL)
Comtex SmarTrend(R) - Wed Jan 22, 9:41AM CST
SmarTrend identified an Uptrend for Exelixis (NASDAQ:EXEL) on November 21st, 2013 at $5.44. In approximately 2 months, Exelixis has returned 51.65% as of today's recent price of $8.25.
Jim Cramer's 'Mad Money' Recap: Buying Retail (Correct)
at The Street - Fri Jan 17, 5:26PM CST
Questions on the continued strength of the consumer will be answered when Amazon reports, Cramer says.
Honigman leads client to victory in U.S. Court of Appeals patent term adjustment ruling
GlobeNewswire - Fri Jan 17, 6:08AM CST
On January 15, 2014, the Court of Appeals for the Federal Circuit (CAFC) decided Novartis AG v. Lee, No. 13-1160 and Exelixis v. Lee (Fed. Cir. Jan. 15, 2014), ruling that the United States Patent and Trademark Office (USPTO) incorrectly interprets the "B period" section of the Patent Term Adjustment (PTA) statute (35 U.S.C. § 154). Honigman Miller Schwartz and Cohn LLP represented Exelixis, Inc. The outcome of this case has ultimately determined how PTA is interpreted for all patentees. In particular, companies in the pharmaceutical and biotechnology industries are likely to benefit, as the regulatory approval process often results in the product being introduced into the market late in the term of the patent.
Exelixis Earnings Hindsight: Down 5.2% in Last 18 Days (EXEL)
Comtex SmarTrend(R) - Mon Mar 10, 7:41AM CDT
Two weeks ago on February 20th, 2014 Exelixis (NASDAQ:EXEL) reported earnings and analysts, on average, expected a loss of $0.38 on sales of $5.7 million. The company actually reported a loss of $0.38 per share on sales of $4.3 million, missing EPS estimates by $0.01 and missing revenue estimates by $1.4 million. Shares of Exelixis have slipped from $7.16 to $6.79, representing a loss of 5.2%, since the company reported earnings 18 days ago.
3 Stocks Under $10 to Trade for Breakouts
at The Street - Wed Mar 05, 5:00AM CST
These under-$10 stocks are within range of triggering breakout trades.
Exelixis Announces Webcast of March 4 Presentation at the 34th Annual Cowen and Company Health Care Conference
Business Wire - Wed Feb 26, 6:56PM CST
Exelixis, Inc. (NASDAQ:EXEL) today announced that Michael M. Morrissey, Ph.D., the company's president and chief executive officer, will present at the 34th Annual Cowen and Company Health Care Conference at 10:00 a.m. EST/7:00 a.m. PST on Tuesday, March 4, 2014 in Boston.
Exelixis Q4 Loss In Line with Expectations - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 21, 11:04AM CST
Exelixis reported fourth quarter 2013 net loss per share of 38 cents, in line with the Zacks Consensus Estimate.
Exelixis' Q4 Loss Widens as Investors Await Key Trial Data
Sean Williams, The Motley Fool - Motley Fool - Thu Feb 20, 4:28PM CST
Cancer-focused biopharmaceutical company Exelixis reported its fourth-quarter earnings results after the bell tonight, delivering lower revenue and a wider loss than in the year-ago period. For the quarter, Exelixis reported net product...
Exelixis Announces Fourth Quarter and Full Year 2013 Financial Results
Business Wire - Thu Feb 20, 3:15PM CST
Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the fourth quarter and year ended December 31, 2013.
Exelixis Inc elects Jeffrey J Hessekiel as EVP & general counsel
M2 - Thu Feb 13, 3:11AM CST
Biotechnology company Exelixis Inc (NasdaqGS:EXEL) revealed on Wednesday the addition of Jeffrey J Hessekiel, JD, as its executive vice president and general counsel.
Exelixis Appoints Executive Vice President and General Counsel
Business Wire - Wed Feb 12, 4:26PM CST
Exelixis, Inc. (NASDAQ: EXEL) today announced the appointment of Jeffrey J. Hessekiel, J.D., as executive vice president and general counsel. Mr. Hessekiel is a veteran legal professional with more than a decade of experience in the biopharmaceutical industry, as well as six years spent in general corporate and litigation practice in Silicon Valley. His legal expertise in pharmaceutical commercialization, compliance, and risk management will benefit Exelixis following its first product launch and in anticipation of top-line data from as many as four phase 3 pivotal trials later this year.
Exelixis Announces February 20th Webcast of Fourth Quarter and Full Year 2013 Financial Results Conference Call
Business Wire - Mon Feb 10, 3:35PM CST
Exelixis, Inc. (NASDAQ: EXEL) will release its fourth quarter and full year 2013 financial results on Thursday, February 20, 2014 after the markets close. The announcement will be followed by a live webcast at 5:00 p.m. EST/ 2:00 p.m. PST. During the webcast, Exelixis management will discuss the Company's financial results, financial outlook and development program and plans for cabozantinib, and also provide a general business update. The webcast may be accessed in the Event Calendar page under Investors & Media at www.exelixis.com.
J. J. Keller and Verizon Join Forces for an All-Inclusive E-Log Solution
Business Wire - Fri Feb 07, 8:48AM CST
Fleets now have an easier way to transition to E-Logs as J. J. Keller & Associates, Inc.(R) introduces the J. J. Keller Compliance Tablet(TM) powered by Verizon.
Western Asset Inflation Management Fund Inc. Portfolio Composition as of December 31, 2013
Business Wire - Thu Feb 06, 7:00AM CST
Western Asset Inflation Management Fund Inc. (NYSE: IMF) announces its portfolio composition as of December 31, 2013.
3 Stocks to Get on Your Watchlist
Sean Williams, The Motley Fool - Motley Fool - Wed Feb 05, 4:11PM CST
I follow quite a lot of companies, so the usefulness of a watchlist to me cannot be overstated. Without my watchlist, I'd be unable to keep up with my favorite sectors and see what's really moving the market. Even worse, I'd be lost when the time...
Exelixis Announces Webcasts of Investor Conference Presentations in February
Business Wire - Fri Jan 31, 4:48PM CST
Exelixis, Inc. (NASDAQ:EXEL) today announced that Michael M. Morrissey, Ph.D., the company's president and chief executive officer, will present at the following two investor conferences in February:
Exelixis Set to Possibly Rebound After Yesterday's Selloff of 1.97%
Comtex SmarTrend(R) - Tue Jan 28, 5:40PM CST
Exelixis (NASDAQ:EXEL) traded in a range yesterday that spanned from a low of $6.81 to a high of $7.22. Yesterday, the shares fell 2.0%, which took the trading range below the 3-day low of $6.85 on volume of 7.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Exelixis Announces Pricing of Overnight Offering of 10,000,000 Shares of Common Stock
Business Wire - Thu Jan 23, 7:33AM CST
Exelixis, Inc. (Nasdaq: EXEL) today announced the pricing of its overnight underwritten public offering of 10,000,000 shares of newly issued common stock at a price to the public of $8.00 per share. Exelixis also granted the underwriter a 30-day option to purchase up to an additional 1,500,000 shares of common stock in connection with the offering. All of the shares of common stock in the offering are being sold by Exelixis. Exelixis anticipates that its aggregate net proceeds from the offering will be $75.6 million after deducting the underwriting discount and estimated offering expenses payable by Exelixis (assuming no exercise of the underwriter's option to purchase additional shares).
Exelixis plans overnight public offering of 10m common shares
M2 - Thu Jan 23, 5:25AM CST
US-based biotechnology company Exelixis Inc (NasdaqGS:EXEL) said on Wednesday that it intends to offer 10m shares of its common stock in an overnight underwritten public offering.
Exelixis Launches Proposed Overnight Public Offering of Common Stock
Business Wire - Wed Jan 22, 3:00PM CST
Exelixis, Inc. (Nasdaq: EXEL) today announced that it plans to offer, subject to market and other conditions, 10,000,000 shares of its common stock in an overnight underwritten public offering. The company expects to grant the underwriter a 30-day option to purchase up to an additional 1,500,000 shares of common stock in connection with the offering. All of the shares of common stock in the offering will be sold by Exelixis. Subject to market and other conditions, the offering is expected to price before 9:30 a.m., EST, on January 23, 2014.
Uptrend Call Working As Exelixis Stock Rises 51.7% (EXEL)
Comtex SmarTrend(R) - Wed Jan 22, 9:41AM CST
SmarTrend identified an Uptrend for Exelixis (NASDAQ:EXEL) on November 21st, 2013 at $5.44. In approximately 2 months, Exelixis has returned 51.65% as of today's recent price of $8.25.
Jim Cramer's 'Mad Money' Recap: Buying Retail (Correct)
at The Street - Fri Jan 17, 5:26PM CST
Questions on the continued strength of the consumer will be answered when Amazon reports, Cramer says.
Honigman leads client to victory in U.S. Court of Appeals patent term adjustment ruling
GlobeNewswire - Fri Jan 17, 6:08AM CST
On January 15, 2014, the Court of Appeals for the Federal Circuit (CAFC) decided Novartis AG v. Lee, No. 13-1160 and Exelixis v. Lee (Fed. Cir. Jan. 15, 2014), ruling that the United States Patent and Trademark Office (USPTO) incorrectly interprets the "B period" section of the Patent Term Adjustment (PTA) statute (35 U.S.C. § 154). Honigman Miller Schwartz and Cohn LLP represented Exelixis, Inc. The outcome of this case has ultimately determined how PTA is interpreted for all patentees. In particular, companies in the pharmaceutical and biotechnology industries are likely to benefit, as the regulatory approval process often results in the product being introduced into the market late in the term of the patent.
